Bristol-Myers Squibb Company

New York Stock Exchange
Back to all articles
Somewhat Bullish +42

Bristol-Myers Squibb stock steadies as ORM-6151 halt offsets strong Q2 results

AI-generated analysis

📉 Bristol-Myers Squibb stock closed at USD 62.84 on September 17, 2026, trading roughly 8.4% below its 52-week high of USD 68.64.

💰 The company reported Q2 2026 revenue of USD 12.97 billion, up 5.7% year over year and beating analyst expectations by 12.9%.

📊 Earnings per share reached USD 2.04, exceeding the consensus estimate of USD 1.60 with a profit margin of 25.57%.

⚠️ Bristol-Myers Squibb decided to halt development of ORM-6151, a blood cancer candidate licensed from Orum Therapeutics, after reviewing Phase 1 data.

💸 The discontinuation of ORM-6151 eliminates up to USD 80 million in contingent milestone payments for the partner company.

📈 The board declared a cash dividend of USD 0.63 per share with an ex-dividend date of October 2, 2026.

🔬 A Phase 3 study for izalontamab brengitecan in combination with osimertinib is scheduled to start on September 30, 2026.

📉 Bristol-Myers Squibb trades at a forward price-earnings multiple of 9.2 times, significantly lower than peer AbbVie's 18.5 times.

📅 The company plans to release Q3 2026 financial results on October 29, 2026.

🏥 Market capitalization is approximately USD 129.46 billion as of September 18, 2026.

Bullish Signals
  • Bristol-Myers Squibb reported Q2 2026 revenue of USD 12.97 billion, a 5.7% year-over-year increase that beat analyst expectations by 12.9%.
  • Earnings per share reached USD 2.04, surpassing the consensus estimate of USD 1.60 by USD 0.44 per share.
  • The company achieved a robust profit margin of 25.57% in the second quarter of fiscal 2026.
  • The board declared a fresh cash dividend of USD 0.63 per share, providing support to income-oriented shareholders.
  • Analysts peg fair value at USD 66.21 per share, suggesting the stock is modestly undervalued relative to its recent close.
  • The company trades at a forward price-earnings multiple of 9.2 times, offering a valuation discount compared to large-cap peer AbbVie.
Risk Factors
  • Bristol-Myers Squibb decided to halt development of ORM-6151, removing a potential future revenue stream from its oncology pipeline.
  • The discontinuation of the ORM-6151 candidate eliminates up to USD 80 million in contingent milestone payments for partner Orum Therapeutics.
Full Analysis
Bristol-Myers Squibb (BMY) shares closed at USD 62.84 on September 17, 2026, reflecting a mixed market reaction where strong second-quarter financial performance was partially offset by the decision to halt development of the oncology candidate ORM-6151. The company reported Q2 2026 revenue of USD 12.97 billion, representing a 5.7% year-over-year increase that significantly beat analyst expectations by 12.9%. Earnings per share reached USD 2.04, surpassing the consensus estimate of USD 1.60 and yielding a profit margin of 25.57%. The strategic decision to discontinue ORM-6151, a blood cancer degrader-antibody conjugate licensed from Orum Therapeutics, removes a potential future revenue stream for Bristol-Myers Squibb. This development also eliminates up to USD 80 million in contingent milestone payments owed to the partner, though the upfront payment of USD 100 million previously received remains intact. The halt follows a review of Phase 1 clinical data conducted across the United States, Europe, and Canada. Despite the pipeline setback, the company's core portfolio continues to generate substantial cash flow, supported by a fresh dividend declaration of USD 0.63 per share with an ex-dividend date of October 2, 2026. Investors view the stock as modestly undervalued compared to peers like AbbVie, trading at a forward price-earnings multiple of 9.2 times versus 18.5 times for the competitor. The market capitalization stands at approximately USD 129.46 billion. Looking ahead, Bristol-Myers Squibb is scheduled to release Q3 2026 results on October 29, 2026, which will provide clarity on whether the strong revenue trajectory can be sustained amidst pipeline adjustments. Additionally, a Phase 3 study for the investigational agent izalontamab brengitecan in combination with osimertinib is set to commence on September 30, 2026, highlighting the diversified nature of the research portfolio as the company manages risks associated with specific asset discontinuations.